MC
CBAY

Menta Capital’s Cymabay Therapeutics CBAY Stock Holding History

Menta Capital’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-18,356
Closed -$127K – 790
2015
Q1 		$127K Buy
+18,356
New +$176K 0.02% 658

Other funds holding CBAY

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Menta Capital's CBAY Position: Q2 2015 in Review

Menta Capital sold out of Cymabay Therapeutics (CBAY) in Q2 2015, closing a stake of 18,356 shares — an estimated $127K sold.

Menta Capital first reported a position in CBAY in Q1 2015 and held it in 1 quarter. The position peaked at $127K in Q1 2015. 29 funds tracked by Wall St. Rank hold CBAY as of Q2 2015.

  • Menta Capital reported no remaining Cymabay Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Menta Capital sold 18,356 Cymabay Therapeutics shares in Q2 2015, an estimated $127K.
  • Menta Capital first reported a position in Cymabay Therapeutics in Q1 2015 and held it in 1 quarter.
  • Menta Capital's Cymabay Therapeutics position peaked at $127K in Q1 2015.
  • 29 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2015.

Based on Menta Capital's 13F filing for Q2 2015, filed 11 Aug 2015.